Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide.
10.19746/j.cnki.issn.1009-2137.2019.05.005
- Author:
Bin-Bin LAI
1
;
Qi-Tian MU
2
;
Yan-Li ZHANG
1
;
Ying CHEN
2
;
Gui-Fang OUYANG
3
Author Information
1. Department of Hematology, Ningbo First Hospital. , Ningbo 315010, Zhejiang Province, China.
2. Laboratory of Stem Cell Transplantation, Ningbo First Hospital. , Ningbo 315010, Zhejiang Province, China.
3. Department of Hematology, Ningbo First Hospital. , Ningbo 315010, Zhejiang Province, China,E-mail:nbhematology@163.com.
- Publication Type:Journal Article
- MeSH:
Arsenic Trioxide;
therapeutic use;
Humans;
Karyotype;
Leukemia, Promyelocytic, Acute;
drug therapy;
Prognosis;
Remission Induction;
Retrospective Studies;
Treatment Outcome;
Tretinoin
- From:
Journal of Experimental Hematology
2019;27(5):1380-1386
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of chromosomal karyotype on the prognosis of patients with acute promyelocytic leukemia (APL) in condition of the maintenance treatment based on arsenic trioxide.
METHODS:The patients with acute promyelocytic leukemia for last 12 years in our hospital were retrospectively collected. The patients mainly treated with arsenic trioxide in maintenance protocol were selected and followed up. All the patients were divided into 3 groups according to cytogenetic data: single t (15; 17) group, t (15; 17) with additional chromosomal abnormality (ACA) group, and normal karyotype group. Then, the prognostic significance of ACAs and complex karyotype were investigated in APL patients.
RESULTS:There were 57 cases in the single t (15; 17) group, in which 8 cases died in the first month after induction treatment with early mortality rate of 14%. There were 21 patients in t (15; 17) with ACA group, in which 4 cases died in the first month with early mortality rate of 19%. There were 15 cases in normal chromosome group, in which 5 cases died in the first month with the early mortality rate of 33.3%. There was no statistical difference in the early mortality among 3 groups. All the remaining 76 patients achieved complete hematological remission. These patients were followed up. The median follow-up time was 43.9 months. Among them, only 2 patients in single t (15; 17) group and 1 patient in t (15; 17) with ACA group relapsed. No patient relapsed in normal karyotype group. The relapse rate was 3.5% in single t (15; 17) group and 4.2% in t (15; 17) with ACA group, respectively. There was no statistical difference in the overall survival and disease-free survival rates among 3 groups. Further analysis showed that the patients with complex chromosome karyotypes had lower relapse-free survival rates, but overall survival rates were not significantly different in 3 group.
CONCLUSION:In general, ACA can not affect the prognosis of patients with acute promyelocytic leukemia in condition of the maintenance treatment based on arsenic trioxide, but the complex chromosomal karyotype may reduce the relapse-free survival rates.
